---
schema_version: "secwatch.filing_event.v1"
accession: "0001615219-25-000040"
form_type: "8-K"
ticker: "DCOY"
cik: "0001615219"
company_name: "Decoy Therapeutics Inc."
filed_at: "2025-03-28T23:59:59+00:00"
generated_at: "2026-05-24T03:05:05.420986+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Salarius amends merger fixing 14.1% legacy ownership; Nasdaq delisting risk from $2.5M equity shortfall

## Summary
- Amendment eliminates cash-based exchange ratio adjustment; legacy Salarius stockholders retain 14.1%, Decoy holders 85.9% of combined company.
- Nasdaq notified Salarius on March 26, 2025 it fails minimum $2.5M stockholders' equity for continued listing.
- Company must submit a compliance plan by May 12, 2025; if accepted, Nasdaq may grant up to 180 days to regain compliance.
- If plan rejected or compliance not regained, Nasdaq may delist; Salarius can request a hearing for up to 180 additional days.

## SEC filing metadata
- accession: 0001615219-25-000040
- form_type: 8-K
- ticker: DCOY
- cik: 0001615219
- company_name: Decoy Therapeutics Inc.
- filed_at: 2025-03-28T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.8
- confidence: high
- sec_items: 1.01, 3.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1615219/000161521925000040/0001615219-25-000040-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1615219/000161521925000040/flks-20250326.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001615219-25-000040
- JSON: https://secwatch.observer/filing/0001615219-25-000040.json
- Plain text: https://secwatch.observer/filing/0001615219-25-000040.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.